Oxytocin

What it is

Oxytocin is a nonapeptide (sequence CYIQNCPLG-NH2) synthesized primarily in the supraoptic nucleus and paraventricular nucleus (PVN) of the hypothalamus and released from the posterior pituitary into the circulation. It differs from vasopressin by two amino acids and both share a disulfide bridge between cysteine residues at positions one and six. Oxytocin binds to specific oxytocin receptors (OXTR) distributed throughout the brain and peripheral tissues, including the myometrium, nucleus accumbens, amygdala, thalamus, pallidum, caudate, putamen, and olfactory bulbs (PMID 40639928; PMID 37951085). Peripheral release occurs in pulses during labor via the Ferguson reflex (cervical pressure activating a feedforward mechanism). Centrally, oxytocin modulates GABAergic, dopaminergic, and serotonergic pathways, enhancing synaptic plasticity and neurogenesis. It interacts with the mesolimbic dopamine system (VTA and nucleus accumbens) and with reward and glutamate systems. Oxytocin also exerts anti-inflammatory, antioxidant, and anti-apoptotic effects, modulates the HPA axis and stress responses, and regulates energy metabolism and food intake via anorexigenic signaling (PMID 34639199; PMID 36768879). Its effects on social behavior are mediated in part through amygdala modulation, particularly the basolateral amygdala. Oxytocin interacts with vasopressin, CRH, orexin, NPY, and endocannabinoid systems (PMID 41905264; PMID 35858094). Epigenetic modifications of the OXTR gene (including DNA methylation) are associated with variability in social and stress-related behaviors. Sex hormones (estrogens, progesterone, testosterone) modulate oxytocin release and OXTR activity, contributing to heterogeneity in oxytocin's effects.

Class: Neuropeptide hormone (cyclic nonapeptide); posterior pituitary hormone

What it's studied for

• Labor induction and augmentation / postpartum hemorrhage prevention Human observational
  • Synthetic oxytocin is administered intravenously to induce and augment labor at increasing rates from 1–3 mIU/min to a maximum of 36 mIU/min at 15–40-minute intervals; 5–10 IU given as IV or IM bolus after delivery to prevent postpartum hemorrhage. High-dose infusions may shorten labor by up to 2 hours but do not lower PMID 38462255 Uvnäs-Moberg K. Am J Obstet Gynecol. 2024.
  • Guidelines recommend starting oxytocin at 2 mUI/min for active-phase dystocia, increasing by 2 mUI/min intervals no faster than every 30 minutes, not exceeding 20 mUI/min IV. Adverse maternal effects include uterine hyperstimulation, rupture, and postpartum hemorrhage. PMID 28238320 Dupont C et al. Gynecol Obstet Fertil Senol. 2017.
• Autism Spectrum Disorder (ASD) — social functioning Human RCT
  • Multilevel meta-analysis of 28 studies (N=726 ASD patients) found oxytocin had beneficial effects on social functioning but not non-social symptom domains. PMID 33400920 Huang Y et al. Neurosci Biobehav Rev. 2021.
  • Review of single- and multiple-dose trials showed mixed results; moderate intervention durations (4–6 weeks) with intermittent dosing (24–32 IU every other day) appear favorable. Enhanced outcomes observed when paired with socially stimulating environments. PMID 39861928 Ricchiuti G et al. J Psychopharmacol. 2025.
  • Single-dose trials consistently showed efficacy on social/neural measures in ASD; repeated-dose trials showed disparate findings, with possible diminishing efficacy at higher or recurrent doses. PMID 38072084 Yamasue H. Peptides. 2024.
  • In a crossover fMRI study of 16 autistic and 21 non-autistic women, oxytocin increased left basolateral amygdala activation and functional connectivity in autistic women but not in non-autistic women. PMID 35254443 Procyshyn TL et al. Soc Cogn Affect Neurosci. 2022.
  • Review noted no FDA-approved pharmacological treatments for core ASD symptoms; neuroimaging evidence supports potential therapeutic benefits of oxytocin. PMID 32711811 Baker E, Stavropoulos KKM. Prog Mol Biol Transl Sci. 2020.
• Postpartum depression (PPD) — maternal affect and caregiving Human RCT
  • Double-blind RCT in 45 mothers with PPD: 24 IU intranasal oxytocin increased maternal positive regard for infant and self-reported positive affect; no effect on maternal sensitivity, negative mood, or physiological stress responses. PMID 40614394 Riem MME et al. Psychoneuroendocrinology. 2025.
  • Oxytocin increased maternal positive regard and positive affect but had no effect on sensitivity, negative mood, or stress physiology in mothers with PPD. PMID 41989096 Riem MME et al. Ned Tijdschr Geneeskd. 2026.
• Schizophrenia — social cognition and symptom reduction Mixed
  • Review of animal and human studies supports a role for oxytocin dysregulation in schizophrenia; potential clinical benefits for social cognition examined. PMID 33670047 Goh KK et al. Int J Mol Sci. 2021.
  • RCT results have been mixed; review argues for focused study using objective outcome measures to determine oxytocin's utility for functional impairment in schizophrenia. PMID 28506922 Bradley ER, Woolley JD. Neurosci Biobehav Rev. 2017.
• Stress responses, anxiety, and resilience Mixed
  • Review: oxytocin neurons activated by stressful stimuli; oxytocin suppresses anxiety and contributes to allostasis and resilience; clinical trials suggest therapeutic benefits for stress-related disorders. PMID 35008574 Takayanagi Y, Onaka T. Int J Mol Sci. 2021.
  • RCT in 44 female adolescents: intranasal oxytocin significantly reduced stress vs. placebo (p=0.012); delivery to the dominant nostril produced greater stress reduction than non-dominant nostril (p=0.034). PMID 40425808 Julius NC et al. Sci Rep. 2025.
  • 86 male participants received intranasal oxytocin or placebo; oxytocin increased average duration of resting EEG networks and decreased occurrence of autonomic-processing network; effects more pronounced in high-anxiety participants. PMID 31558733 Schiller B et al. Sci Rep. 2019.
• Food intake regulation and obesity Mixed
  • Review: central oxytocin signaling potently reduces food intake in humans and animal models; reduces meal size via amplification of within-meal satiation signals; interacts with leptin, AgRP, and MCH systems. PMID 34639199 Liu CM et al. Int J Mol Sci. 2021.
  • Intranasal oxytocin acutely limits meal intake and consumption of palatable snacks in normal-weight and obese individuals; mechanisms may involve both metabolic and psychosocial pathways. PMID 28284882 Spetter MS, Hallschmid M. Physiol Behav. 2017.
  • Clinical studies suggest intranasal oxytocin decreases energy-induced and reward-induced eating, supports cognitive control of food choices, and improves glucose homeostasis; effectiveness may be BMI-dependent. PMID 28590323 Olszewski PK et al. Curr Opin Endocrinol Diabetes Obes. 2017.
• Glucose regulation / metabolic effects Human RCT
  • Double-blind crossover RCT in 25 men with type 2 diabetes: intranasal oxytocin (24 IU) 60 min before oGTT did not alter glucose, insulin, or C-peptide AUC. Oxytocin increased plasma oxytocin concentrations and reduced heart rate but had no acute glucoregulatory effect. PMID 39118203 Goll N et al. Diabetes Obes Metab. 2024.
• Maternal behavior and parental caregiving Mixed
  • Review: oxytocin-dopamine interactions regulate maternal motivation and pup-approach behaviors; oxytocin-serotonin interactions regulate nursing, aggression, anxiety, and stress coping in the postpartum period. PMID 35858105 Grieb ZA, Lonstein JS. Philos Trans R Soc Lond B Biol Sci. 2022.
  • Review: oxytocin is indispensable for milk ejection in all mammals; can facilitate onset of parental behavior or parental behavior under stressful conditions. PMID 28812267 Yoshihara C et al. Curr Top Behav Neurosci. 2018.
• Prader-Willi syndrome (PWS) Mixed
  • Review: oxytocin involved in food motivation and hyperphagia relevant to PWS; clinical trials show discrepant results; authors propose dynamic (PRN) dosing paired with social interventions. PMID 39455012 Josselsohn A et al. Pharmacol Ther. 2024.
  • Review: oxytocin regulates thermogenesis; disruption of oxytocin's thermoregulatory mechanism manifests in PWS through thermosensory abnormalities and altered skeletal muscle tone. PMID 38396741 Camerino C. Int J Mol Sci. 2024.
• Alzheimer's disease — cognitive and memory effects Animal studies only
  • Systematic review: animal model studies consistently demonstrate oxytocin administration mitigates memory deficits in AD models via reduced microglial-driven inflammation and decreased amyloid-beta deposition; no robust human data available. PMID 40417765 Shafigh E et al. Curr Alzheimer Res. 2025.
• Drug dependence and addiction (preclinical and clinical) Mixed
  • Review of clinical and preclinical studies: oxytocin administration can reduce drug-induced dependence despite some conflicting results; dose-dependent effects vary across brain regions. PMID 40639928 Esmaili-Shahzade-Ali-Akbari P et al. Eur J Neurosci. 2025.
  • Review: preclinical studies show oxytocin alleviates nicotine withdrawal-induced anxiety, reduces somatic symptoms, suppresses cue-induced nicotine seeking; clinical trials show potential in reducing craving intensity but variable relapse prevention. PMID 41687409 Thanekar R et al. Neuropeptides. 2026.
• Social cognition, prosocial behavior, and cooperation Human RCT
  • Review: oxytocin modulates care-based altruism, cooperation, and conflict; therapeutic potential for psychiatric disorders characterized by social dysfunction. PMID 32981445 Marsh N et al. Neuroscientist. 2021.
  • RCT (N=304): intranasal oxytocin (24 IU) doubled women's sensitivity to partner choices in prisoner's dilemma against computers and doubled unconditional cooperation with humans; vasopressin increased sensitivity across sexes. PMID 32207359 Neto ML et al. J Psychopharmacol. 2020.
  • RCT (N=79): oxytocin enhanced group-based guilt and compensation for victims in high moral disengagement individuals. PMID 39059227 Li Z, Xu M. Psychoneuroendocrinology. 2024.
• Non-social executive function and cognitive flexibility Human RCT
  • Preregistered meta-analysis of 13 studies (20 effect estimates): no overall significant effect of oxytocin on non-social executive functions (Hedges' g=0.07, p=0.30); largest effect for cognitive flexibility (Hedges' g=0.20, p=0.02). PMID 39827218 Kang H et al. Mol Psychiatry. 2025.
• PTSD Human observational
  • Intranasal oxytocin showed some alleviating effects on PTSD symptoms in the study by Koch et al., but effects were small and clinical significance remains to be determined. PMID 34346654 Dumont GJH. Ned Tijdschr Geneeskd. 2021.
• Eating disorders Mixed
  • Review: brain administration of oxytocin in animals attenuates food intake and reduces body weight; acute intranasal oxytocin curbs calorie intake in normal-weight and obese individuals; evidence for oxytocin's role in anorexia nervosa; data in bulimia nervosa and binge eating disorder are scarce. PMID 29189166 Giel K et al. Curr Neuropharmacol. 2018.
• Neonatal neuroprotection (preclinical) Animal studies only
  • Review: preclinical studies strongly suggest endogenous and synthetic oxytocin can regulate CNS inflammatory response in prematurity and perinatal brain injury; no robust human data. PMID 38145743 Baud O, Knoop M. Gynecol Obstet Fertil Senol. 2024.
• Social anxiety Mixed
  • Review: intranasal oxytocin in humans has favorable effects on social anxiety symptomatology; associations found between social anxiety and OXTR gene alleles and plasma oxytocin levels. PMID 28590323 Jones C et al. Dialogues Clin Neurosci. 2017.
• Hypopituitarism / craniopharyngioma — metabolic and neuropsychological deficits Mixed
  • Review: oxytocin deficiency may be evident in hypopituitarism and craniopharyngioma; preliminary data hint at benefits for cognitive empathy and metabolic disturbances; optimal mode of administration and long-term safety profile not yet established. PMID 30506703 Bhargava R et al. Clin Endocrinol. 2019.
• Male sexual dysfunction (erection, ejaculation, libido) Mixed
  • Review: oxytocin can induce penile erection in multiple brain regions; nasal administration may increase sexual desire; correlation with premature ejaculation suggested. PMID 33354958 Wang H, Chen Y. Natl J Androl. 2020.
• Milk microRNA composition regulation Human observational
  • Oxytocin-treated mammary cells and colostrum showed upregulation of miR-148a and downregulation of miR-320 compared to untreated; exogenous oxytocin administration to mothers altered colostrum miRNA composition. PMID 34371509 Gutman-Ido E et al. J Pediatr Gastroenterol Nutr. 2022.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.